Blood Test Panel Articles & Analysis: Older
3 news found
The focus of this strategic investment is the advancement of the HCC Panel toward commercial launch in the United States, transfer of the HCC Panel technology to Fosun Pharma’s diagnostic subsidiary for commercialization in China, and further development of pipeline tests for liver fibrosis and cholangiocarcinoma, the second most prevalent ...
Under the terms of the agreement, Fosun Pharma receives 40% of Glycotest Inc. and an exclusive license to manufacture and sell the Glycotest Inc. HCC Panel blood test in China in return for a royalty on sales to Glycotest Inc.. ...
Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry. ...